What is Licartin and CIK used for?

Licartin and CIK is indicated for Hepatocellular carcinoma, Advanced hepatocellular carcinoma.

Who makes Licartin and CIK?

Licartin and CIK is developed by Tianjin Medical University Cancer Institute and Hospital.

What development phase is Licartin and CIK in?

Licartin and CIK is FDA-approved (marketed).

What are the side effects of Licartin and CIK?

Common side effects include Fever, Chills, Fatigue, Infusion-related reactions.

Last reviewed 2026-04-22 · How we verify

Licartin and CIK

Tianjin Medical University Cancer Institute and Hospital · FDA-approved active Biologic

Licartin is a recombinant human-mouse chimeric monoclonal antibody targeting hepatocellular carcinoma cells, while CIK refers to cytokine-induced killer cells used in adoptive cell immunotherapy.

Licartin is a recombinant human-mouse chimeric monoclonal antibody targeting hepatocellular carcinoma cells, while CIK refers to cytokine-induced killer cells used in adoptive cell immunotherapy. Used for Hepatocellular carcinoma, Advanced hepatocellular carcinoma.

At a glance

Generic name	Licartin and CIK
Sponsor	Tianjin Medical University Cancer Institute and Hospital
Drug class	Monoclonal antibody (Licartin); Adoptive cell therapy (CIK)
Target	HAb18G/CD147 antigen (Licartin); Multiple (CIK cells)
Modality	Biologic
Therapeutic area	Oncology
Phase	FDA-approved

Mechanism of action

Licartin binds to HAb18G/CD147 antigen expressed on hepatocellular carcinoma cells, facilitating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. CIK cells are ex vivo expanded lymphocytes with both T-cell and NK-cell characteristics that provide adoptive immunotherapy. The combination leverages both targeted monoclonal antibody therapy and cellular immunotherapy mechanisms.

Approved indications

Hepatocellular carcinoma
Advanced hepatocellular carcinoma

Common side effects

Fever
Chills
Fatigue
Infusion-related reactions

Key clinical trials

A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Licartin and CIK CI brief — competitive landscape report
Licartin and CIK updates RSS · CI watch RSS
Tianjin Medical University Cancer Institute and Hospital portfolio CI